Evidence map›Paper›PMID 36692509›Full record

ArticleDiabetologia2023

Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.

Shao-Wen Weng, Jian-Ching Wu, Feng-Chih Shen, Yen-Hsiang Chang, Yu-Jih Su, Wei-Shiung Lian, Ming-Hong Tai, Chia-Hao Su, Jiin-Haur Chuang, Tsu-Kung Lin and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Exercise elicits mitonuclear protein imbalance and UPRJournal of physiology and biochemistry · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Chaperonin in health and disease.Molecular biomedicine · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Establishment and Evaluation of HepG2 Cell Insulin Resistance Model.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Shao-Wen WengDepartment of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Jian-Ching WuCenter for Mitochondrial Research and Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Feng-Chih ShenDepartment of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Yen-Hsiang ChangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yu-Jih SuDepartment of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Wei-Shiung LianCenter for Mitochondrial Research and Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Ming-Hong TaiInstitute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
Chia-Hao SuInstitute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Jiin-Haur ChuangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Tsu-Kung LinSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chia-Wei LiouSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Tian-Huei ChuMedical Laboratory, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
Ying-Hsien KaoDepartment of Medical Research, E-Da Hospital, Kaohsiung, Taiwan.
Feng-Sheng WangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. wangfs@ms33.hinet.net.
Pei-Wen WangDepartment of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. wangpw@adm.cgmh.org.tw.
Chang Gung University · TWKaohsiung Chang Gung Memorial Hospital · TWChang Gung University of Science and Technology · TWE-Da Hospital · TWKaohsiung Armed Forces General Hospital · TWNational Sun Yat-sen University · TW

Funding

Chang Gung Memorial Hospital CRRPG8K0051Kaohsiung Chang Gung Memorial Hospital CMRPG8H0203Ministry of Science and Technology, Taiwan MOST 109-2314-B-182A-161
6 · The paper itself

Abstract

aims/hypothesisThe mitochondrial chaperonin heat shock protein (HSP) 60 is indispensable in protein folding and the mitochondrial stress response; however, its role in nutrient metabolism remains uncertain. This study investigated the role of HSP60 in diet-induced non-alcoholic fatty liver disease (NAFLD).

methodsWe studied human biopsies from individuals with NAFLD, murine high-fat-diet (HFD; a diet with 60% energy from fat)-induced obesity (DIO), transgenic (Tg) mice overexpressing Hsp60 (Hsp60-Tg), and human HepG2 cells transfected with HSP60 cDNA or with HSP60 siRNA. Histomorphometry was used to assess hepatic steatosis, biochemistry kits were used to measure insulin resistance and glucose tolerance, and an automated home cage phenotyping system was used to assess energy expenditure. Body fat was assessed using MRI. Macrophage infiltration, the lipid oxidation marker 4-hydroxy-2-nonenal (4-HNE) and the oxidative damage marker 8-hydroxy-2'-deoxyguanosine (8-OHdG) were detected using immunohistochemistry. Intracellular lipid droplets were evaluated by Nile red staining. Expression of HSP60, and markers of lipogenesis and fatty acid oxidation were quantified using RT-PCR and immunoblotting. Investigations were analysed using the two-way ANOVA test.

resultsDecreased HSP60 expression correlated with severe steatosis in human NAFLD biopsies and murine DIO. Hsp60-Tg mice developed less body fat, had reduced serum triglyceride levels, lower levels of insulin resistance and higher serum adiponectin levels than wild-type mice upon HFD feeding. Respiratory quotient profile indicated that fat in Hsp60-Tg mice may be metabolised to meet energy demands. Hsp60-Tg mice showed amelioration of HFD-mediated hepatic steatosis, M1/M2 macrophage dysregulation, and 4-HNE and 8-OHdG overproduction. Forced HSP60 expression reduced the mitochondrial unfolded protein response, while preserving mitochondrial respiratory complex activity and enhancing fatty acid oxidation. Furthermore, HSP60 knockdown enhanced intracellular lipid formation and loss of sirtuin 3 (SIRT3) signalling in HepG2 cells upon incubation with palmitic acid (PA). Forced HSP60 expression improved SIRT3 signalling and repressed PA-mediated intracellular lipid formation. SIRT3 inhibition compromised HSP60-induced promotion of AMP-activated protein kinase (AMPK) phosphorylation and peroxisome proliferator-activated receptor α (PPARα levels), while also decreasing levels of fatty acid oxidation markers. CONCLUSION/

interpretationMitochondrial HSP60 promotes fatty acid oxidation while repressing mitochondrial stress and inflammation to ameliorate the development of NAFLD by preserving SIRT3 signalling. This study reveals the hepatoprotective effects of HSP60 and indicates that HSP60 could play a fundamental role in the development of therapeutics for NAFLD or type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceNon-alcoholic Fatty Liver DiseaseSirtuin 3AnimalsChaperonin 60Diet, High-FatFatty AcidsHumansLipid MetabolismLipidsLiverMiceMice, Inbred C57BLMitochondrial ProteinsChaperonin 60Fatty AcidsHSPD1 protein, humanLipidsMitochondrial ProteinsSIRT3 protein, humanSirt3 protein, mouseSirtuin 3Heat shock protein 60Lipid metabolismMitochondriaProinflammationβ-oxidation

Identifiers

PMID36692509
OpenAlexW4317830845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.